Type i interferon receptor deficiency prevents murine Sjögren's syndrome

Journal of Dental Research

Volumn 92, Issue 5, 2013, Pages 444-449

  Szczerba, B M ^a   Rybakowska, P D ^a   Dey, P ^a   Payerhin, K M ^a   Peck, A B ^a   Bagavant, H ^a,b   Deshmukh, U S ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

autoimmunity; interferons; mouse; salivary gland; sialoadenitis; xerostomia

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; AUTOANTIBODY;

ANIMAL; ARTICLE; BLOOD; COMPARATIVE STUDY; DACRYOCYSTITIS; DISEASE MODEL; FEMALE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; MOUSE MUTANT; MOUSE STRAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; SALIVATION; SIALOADENITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME;

ANIMALS; AUTOANTIBODIES; DACRYOCYSTITIS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; SALIVATION; SIALADENITIS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

EID: 84876350685     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034513483315     Document Type: Article

References (29)

1. Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol. 2009 ; 183: 6021-6029
2. Bagavant H, Thompson C, Ohno K, Setiady Y, Tung KS. Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. Int Immunol. 2002 ; 14: 1397-1406
3. Carr AJ, Ng WF, Figueiredo F, Macleod RI, Greenwood M, Staines K. Sjögren's syndrome - an update for dental practitioners. Br Dent J. 2012 ; 213: 353-357
4. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. Arthritis Rheum. 2002 ; 46: 1390-1398
5. Delaleu N, Nguyen CQ, Peck AB, Jonsson R. Sjögren's syndrome: studying the disease in mice. Arthritis Res Ther. 2011 ; 13: 217
6. Deshmukh US, Lewis JE, Gaskin F, Kannapell CC, Waters ST, Lou YH, et al. Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies. J Exp Med. 1999 ; 189: 531-540
7. Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med. 2009 ; 38: 42-47
8. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun. 2009 ; 10: 285-296
9. Glaser JR, Glaser EM. Stereology, morphometry and mapping: the whole is greater than the sum of the parts.. J Chem Neuroanat. 2000 ; 20: 115-126
10. Hasegawa H, Inoue A, Kohno M, Muraoka M, Miyazaki T, Terada M, et al. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis Rheum. 2006 ; 54: 1174-1183
11. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005 ; 52: 1534-1544
12. Horvath S, Nazmul-Hossain AN, Pollard RP, Kroese FG, Vissink A, Kallenberg CG, et al. Systems analysis of primary Sjögren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model. Arthritis Res Ther. 2012 ; 14: R238
13. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957 ; 147: 258-267
14. Kang KY, Kim HO, Kwok SK, Ju JH, Park KS, Sun DI, et al. Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther. 2011 ; 13: R179
15. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest. 2006 ; 116: 2456-2463
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001 ; 25: 402-408
17. Nandula SR, Scindia YM, Dey P, Bagavant H, Deshmukh US. Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjögren's syndrome-like disease. Oral Dis. 2011 ; 17: 801-807
18. Nandula SR, Dey P, Corbin KL, Nunemaker CS, Bagavant H, Deshmukh US. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. J Oral Pathol Med. 2013 ; 42: 66-72
19. Nguyen C, Singson E, Kim JY, Cornelius JG, Attia R, Doyle ME, et al. Sjögren's syndrome-like disease of C57BL/6.NOD-Aec1 Aec2 mice: gender differences in keratoconjunctivitis sicca defined by a cross-over in the chromosome 3 Aec1 locus. Scand J Immunol. 2006 ; 64: 295-307
20. Nguyen CQ, Sharma A, Lee BH, She JX, McIndoe RA, Peck AB. Differential gene expression in the salivary gland during development and onset of xerostomia in Sjögren's syndrome-like disease of the C57BL/6.NOD-Aec1Aec2 mouse. Arthritis Res Ther. 2009 ; 11: R56
21. Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, Busto P, et al. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J Immunol. 2010 ; 184: 796-806
22. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med. 2003 ; 197: 777-788
23. Shirota Y, Illei GG, Nikolov NP. Biologic treatments for systemic rheumatic diseases. Oral Dis. 2008 ; 14: 206-216
24. St Clair EW, Levesque MC, Luning Prak ET, Vivino FB, Alappatt CJ, Spychala ME, et al. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013 ;:
25. Trinchieri G. Type I interferon: friend or foe?. J Exp Med. 2010 ; 207: 2053-2063
26. Vakaloglou KM, Mavragani CP. Activation of the type I interferon pathway in primary Sjögren's syndrome: an update. Curr Opin Rheumatol. 2011 ; 23: 459-464
27. Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis. 2011 ; 70: 1153-1159
28. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol. 2010 ; 6: 529-537
29. Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol. 2007 ; 178: 6876-6885